Introduction
. Some recent studies have demonstrated receptormediated coronary endothelial dysfunction [12, 13] and that Syndrome X (angina, normal coronary arteriogram and pacing and acetylcholine-induced coronary flow responses positive exercise test) [1] remains a controversial subject correlate [14] , but whether there is generalised endothelial in respect of its identity, mechanisms, pathogenesis, predysfunction and whether it involves flow-mediated dilatavalence and clinical importance. Continuing uncertainties tion [15] [16] [17] [18] remains to be established. Endothelial reflect probable differences in patient selection in the dysfunction, moreover, is relatively common, and whether published studies, the diagnostic dependence on exclusion the association is coincidental or causal remains to be of other conditions with which it may co-exist, and confirmed. interpretative limitations of investigative methods used. A We measured brachial artery flow-related dilatation in a number of studies have provided implicit evidence of group of patients with Syndrome X, defined also as having coronary microvascular dysfunction [2] [3] [4] [5] [6] [7] , but whether the positive thallium scans and no known cause of endothelial angina always reflects myocardial ischaemia is less certain dysfunction, and in a control group of normal subjects.
201
To test whether the positive thallium scans might represent abnormalities of myocardial potassium homeo-stasis rather than of perfusion, as has been suggested [19] , and serum homocysteine .15 mmol / l (confirmed during 201 99 the study). All patients continued on stable anti-anginal exercise scans with thallium and with technetium medication except that nitrovasodilator drugs were stopped tetrafosmin were compared.
for 24 h before each study. One of the 4 post-menopausal L-arginine supplementation improves endothelial funcwomen was taking hormone replacement therapy. No tion in some conditions where it is impaired [20] [21] [22] , but alcohol or caffeine-containing beverage was taken during has been shown not measurably to increase endotheliumthe 24 h before each study. dependent vasodilatation in normal subjects with normal A control group of 10 normal (normotensive, non-smokendothelial function [23] . Parenteral L-arginine has been ing) subjects, matched for age, sex and serum cholesterol, reported acutely to improve acetylcholine-induced corwere randomly selected, blind as to their characterisation onary vasodilator responses [24] in Syndrome X, though other than by the features required for matching, from 300 the evidence is conflicting [25] . The Syndrome X patients normal subjects in the cumulative databank of patients were accordingly entered into a placebo-controlled trial of similarly studied by the same investigators. L-arginine, with measurement of flow-mediated dilatation, exercise capacity and radionuclide scans. Patients were studied fasting in a temperature-controlled inferior defect. Chest x-ray and echocardiogram were room (21-238C) following 15 min supine rest. Measurenormal in all patients. None had bronchopulmonary or ments were made at baseline, during hand hyperaemia at 1 other serious disease. Exclusion criteria were conditions and 2 min after deflation of a wrist cuff inflated to known to be associated with endothelial dysfunction, ie suprasystolic pressure for 5 min, and at 3 min after 400 mg blood pressure .150 / 90 mm Hg, present or past active or sublingual glyceryl trinitrate (GTN) -protocols developed heavy passive smoking, serum cholesterol .6.5 mmol / l, in preliminary studies with confirmation of reproducibility the measure of flow-related dilatation, and the peak flow scans repeated after redistribution. Technetium tetrafos-(averaged over the first 15 s after cuff release) as the min scans were performed following injections resting and measure of hyperaemic flow.
at peak exercise. Conventional short axis, vertical long axis and horizontal long axis slices were displayed and analysed by 2 experienced observers independently and blind 2.2.2. L-Arginine study in Syndrome X to clinical information. The semi-quantitative analysis was The Syndrome X patients were entered into a doublecarried out from polar plots [30] . Technetium scans on blind randomised placebo-controlled cross-over trial of 4 placebo were used to compare with thallium scans, taking weeks oral L-arginine. This comprised two 4-week treatadvantage of the ethically approved inclusion of techment periods with oral L-arginine or matching placebo in netium scans in the arginine trial protocol. randomised order, double-blind, without an intervening washout period. Patients were prescribed 7 g oral L-2.2.6. Blood samples and assays arginine twice a day (twenty-eight 500 mg coated tablets
Fasting venous blood was sampled from the antecubital per day), with food, or the equivalent amount of inactive vein before measuring brachial artery responses. Blood placebo (lactose) coated tablets. This regime was chosen was drawn into vials containing EDTA (homocysteine), because it was reported to be well tolerated and to achieve lithium-heparin (nitrite and nitrate), SSTTM (gel and clot plasma levels approximately twice normal [23] .
activator) (L-arginine, fasting lipids) and sodium citrate Each patient was studied at the same time of day (i) 7
(VWF antigen). Plasma and serum were separated within 1 days before the start of this trial (Day 27) (for equipment h by centrifugation at 4400 rpm for 10 min and stored at familiarisation and to minimise training effect), (ii) at the 2708C until analysis. start of the study (Day 0), and (iii) and (iv) at the end of each treatment period (Day 28 and Day 56), providing data 2.2.7. L-arginine at baseline (Day 0), after 4 weeks of L-arginine, and after 4 Serum L-arginine was measured by an ion-exchange weeks placebo. Investigations were performed in the amino acid analyser (BIOTRONIK LC5001) using following order on each study day: (i) clinical assessment Ninhydrin detection [31] . Quinton Metabolic Cart, calibrated before each study, as previously described [29] . Inspired and expired oxygen Data are given in the text and tables as group mean was measured using a Zirconia oxide high temperature (SD). The Shapiro-Wilk test was used to test for normalifurnace sensor, carbon dioxide concentration using an ty. All data were normal apart from data for hyperaemic infra-red absorption sensor, and expiratory flow with a blood flow which were consequently logarithm-transformpneumotachometer.
ed. Baseline data for Syndrome X and normal controls Table 2 were compared using a one-way ANOVA. Data in the Syndrome X and normal control groups: brachial artery study Syndrome X arginine trial were compared using ANOVA. the groups being significant (P,0.001) ( Table 2 ). There * P,0.05 vs. normal controls (ANOVA).
was no difference in hyperaemic flow or GTN-induced dilatation between the Syndrome X and control groups. Table 3 Syndrome X -brachial artery study: L-arginine vs. placebo. Serum levels of homocysteine, nitrate, nitrite and VWF diastolic BP (mmHg) 66 (5) 69 (2) antigen were unchanged by L-arginine.
L-arginine study in Syndrome X
Mean (SD). * P,0.05 vs. placebo. placebo, suggesting a quantitative relationship (though the correlation did not quite achieve significance). The 'ratepressure product' (RPP) (heart rate3systolic blood pressure) at peak exercise was unchanged by L-arginine. Similar radionuclide defects at peak symptom-limited exercise were demonstrated at the same site in each patient 99 on both of the technetium tetrafosmin scans and the 201 thallium scan [30] . Peak respiratory exchange ratio (V CO /V O ) was ,1.0 on every test, indicating that the 2 2 symptom-limited exercise was not associated with limitation of skeletal muscle perfusion to the point of anaerobic metabolism [29].
Flow-related vasodilatation

Discussion
The finding of similar regional defects of myocardial 201 99 uptake with thallium and with technetium tetrafosmin in all cases supports the interpretation of thallium scans in handling as has been suggested [19] . 3). The increase in flow-related dilatation appeared to be using xenon [36, 37] to measure perfusion and with the related (though not significantly) to the increase in serum inference of microvascular dysfunction. L-arginine concentration Fig. 1. GTN- 
The study showed loss of flow-related brachial artery heart rate, blood pressure, basal and hyperaemic brachial dilatation in the Syndrome X patients, compared with the artery blood flow and diameter were similar on L-arginine matched normal control group, while endothelium-indeand placebo.
pendent GTN responses were unimpaired. Flow-related dilatation is due predominantly to endothelial nitric oxide 3.2.4. Exercise test (NO) activity [38, 39] and its loss in disease relates to the The limiting symptom of angina (associated with short-NO-mediated component [39] . Endothelial dysfunction, ness of breath and fatigue in 2 patients each) was in every thus measured, demonstrates in particular the loss of patient similar in all tests (see Table 4 ). On L-arginine, physiologically integrative flow-mediated dilatation (previpeak V O was greater than on placebo (117 [15]%, ously not found to be impaired in Syndrome X [15-17]), 2 P,0.05), and exercise duration was similarly longer (111 as distinct from endothelial receptor-mediated dilatation [24] %): the increase in exercise duration was 120 [23] % with its different cell signalling pathways [18] . One when serum arginine levels were .40% higher, compared previous similar study [17] found no significant loss of with 0 [14]% when they were only ,20% higher than on flow-related dilatation but a decrease in hyperaemic flow, not apparent in the present study: other metabolic dilator demonstration of this phenomenon. Heterogeneity of mimechanisms generally compensate in this respect for loss crovascular flow has been modelled experimentally by of NO activity alone [40, 41] . The present study differs coronary microembolization and shown to result in infrom many previous reports in being restricted to patients creased adenosine output and resting flow, attributable to with confirmatory evidence of microvascular dysfunction local foci of adenosine-mediated 'steal', with myocardial from radionuclide scans, thereby avoiding potential diluischaemia occurring only with heavier loads of microemtion of the Syndrome X study group by patients with boli [48] . This accords with evidence that increased non-cardiac pain, and to patients with no known cause of adenosine production can compensate for lack of NO endothelial dysfunction -restricting thereby the number of production in increasing flow to meet increased energy patients available. The finding of endothelial dysfunction, consumption [40, 41] . notwithstanding, adds weight to the view that endothelial Microvascular heterogeneity could thus account for (i) dysfunction is an intrinsic feature of the syndrome.
increased resting coronary flow [49, 5, 7] , (ii) enhanced pain Oral L-arginine supplementation restored flow-related perception [50] [51] [52] even in the absence of ischaemia, due dilatation in the brachial artery of these Syndrome X to local accumulation of adenosine [48] which is an algetic patients. The data suggest that the increase in dilatation agent [53, 54] and which could also lower the threshold to and in exercise duration was related to the arginine level other painful stimuli; (iii) potassium-related ST depression measured at the time of study, raising the possibility that it due to opening of K channels by adenosine [55] ; (iv) ATP may reflect an acute effect of L-arginine. L-arginine did not pulmonary microvascular dysfunction as suggested by increase resting artery diameter or GTN-induced dilatation exercise-related perfusion-ventilation mismatch in the abbut only flow-related dilatation, implying that it specificalsence of heart failure [45] ; (v) the frequent absence of ly improved flow-mediated NO production [38, 39] . Nonconfirmatory evidence of ischaemic changes in cardiac specific dilator effects, as reported with acute high dose contraction, perfusion or metabolism [8] [9] [10] [11] [56] [57] [58] , which parenteral administration [42] , are unlikely at the 25-fold may indicate absence of ischaemia or limited investigative lower levels achieved here.
resolution and sensitivity for demonstrating widespread L-Arginine also increased V O max and the duration of small foci of ischaemia; and (vi) the findings of a recent 2 symptom-limited exercise, confirmed as limited with simistudy which, by measuring trans-myocardial intermediary lar radionuclide defects in every case. The radionuclide metabolite levels, effectively excluded myocardial isdefects were unaltered by L-arginine, consistent with the chaemia in most Syndrome X patients during pacingfact that they were measured at the peak of symptominduced angina with ST depression, but showed that some limited exercise in each case. Changes in the 'rate-pressure did develop myocardial ischaemia (JP Bagger, pers. product' (RPP) at peak exercise provide a measure of comm.). Myocardial ischaemia may indeed be not an changes in cardiac workload. The RPP was unchanged by intrinsic feature of the Syndrome but a manifestation of its L-arginine. This suggests that the improvement in exercise more severe presentation. An involvement of adenosine in duration and V O was not attributable to an increase in the pathogenesis of Syndrome X has been proposed 2 max maximal coronary perfusion such as would enable an previously by Maseri and others [59] [60] [61] [62] . increase in cardiac work, but rather to improved skeletal Insulin resistance, with increased pro-insulin secretion muscle perfusion relative to cardiac workload. and high triglyceride but low HDL serum levels as in The study provides support for the still debated view metabolic Syndrome X, has also now been recognised to that Syndrome X is characterised by endothelial dysfuncbe a feature of cardiac Syndrome X [63-65]. It too might tion. The improvement with L-arginine adds weight to this be a consequence of endothelial dysfunction causing conclusion. Endothelial dysfunction is shown to affect microvascular heterogeneity of skeletal muscle flow, given flow-mediated dilatation and not to be limited to the that glucose uptake can be influenced by insulin-stimulated coronary arteries but generalised. Generalised endothelial NO-mediated increase in blood flow [66] which could dysfunction could account for many of the disparate become locally rate-limiting. Endothelial dysfunction is features of Syndrome X, including systemic [43] and strongly, albeit probably not universally, associated with potential cerebral [44] and pulmonary microvascular maniinsulin resistance in different disease states [47] , but festations [45] . Of particular interest is the experimental whether it directly causes insulin resistance remains conevidence that maintenance of microvascular distribution of troversial [67] . There may be regional and pathological flow depends on normal flow-mediated NO production differences in endothelial dysfunction in different con- [46] . Endothelial dysfunction could thus prejudice tissue ditions. Endothelial dysfunction may moreover be associperfusion relative to 'macro-flow'. Conversely, improveated with structural microvascular changes [68] , though ment in endothelial function would improve homogeneity whether this is a feature of Syndrome X remains uncertain of microvascular distribution and tissue perfusion [47] . [69, 6] . This could account for the improvement in exercise
The cause of endothelial dysfunction in those Syndrome tolerance and V O by L-arginine with unchanged rate-X patients in whom other causes are excluded, as in the 2max pressure-product, and may be the first recognised clinical present study, remains to be established. Whether endo- 
